Hims & Hers Health, a telehealth company, has announced plans to cut around 4% of its workforce, affecting 68 employees. This move comes in response to the U.S. Food and Drug Administration's decision to ban compounded versions of Novo Nordisk's GLP-1 weight-loss drug, Wegovy. The ban, effective from May 22, 2025, has already impacted the company's finances and triggered a significant share value drop.
The impact of the FDA's ban is notable, as Hims & Hers previously offered more affordable compounded versions of Wegovy, which had been a considerable revenue driver. Reuters reported that the company's stock value has decreased by 14% since the announcement. Despite this setback, Hims & Hers saw a 111% increase in year-over-year revenue during the first quarter of 2025, with sales from GLP-1 weight-loss drugs generating $200 million of its $1.5 billion revenue in 2024.
In response to the regulatory changes, Hims & Hers is seeking partnerships with Novo Nordisk to secure access to branded Wegovy for its patients. Simultaneously, the company aims to broaden its service offerings to new treatment areas including low testosterone, menopause, and sleep treatments. While implementing these strategic adjustments, Hims & Hers maintains plans to hire for roles crucial to its long-term growth, despite the current layoffs.